EMEND® (aprepitant)

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
MERCK

 

References

  1. Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer. 2004;12:626–633.
  2. Gralla RJ, Osoba D, Kris MG, et al, for the American Society of Clinical Oncology. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971–2994.
  3. Osoba D, Zee B, Warr D, et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer. 1997;5:307–313.
  4. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2005;13:117–121.
  5. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999;4:191–196.
  6. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting–two new agents. J Support Oncol. 2003;1:89–103.
  7. National Comprehensive Cancer Network. Clinical practice guidelines in oncology–v.2.2006: antiemesis. Available at: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed October 12, 2006.
  8. National Comprehensive Cancer Network. Clinical practice guidelines in oncology–v.2.2006: non-small cell lung cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed October 12, 2006.
  9. National Comprehensive Cancer Network. Clinical practice guidelines in oncology–v.1.2006: small cell lung cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf. Accessed October 12, 2006.
  10. National Comprehensive Cancer Network. Clinical practice guidelines in oncology–v.1.2006: head and neck cancers. Available at: http://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf. Accessed October 12, 2006.
  11. National Comprehensive Cancer Network. Clinical practice guidelines in oncology–v.2.2006: non-Hodgkin’s lymphoma. Available at: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf. Accessed October 12, 2006.
  12. National Comprehensive Cancer Network. Clinical practice guidelines in oncology–v.2.2006: breast cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed October 12, 2006.
  13. National Comprehensive Cancer Network. Clinical practice guidelines in oncology–v.1.2006: ovarian cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf. Accessed October 12, 2006.
  14. National Comprehensive Cancer Network. Clinical practice guidelines in oncology–v.1.2006: Hodgkin disease/ lymphoma. Available at: http://www.nccn.org/professionals/physician_gls/PDF/hodgkins.pdf. Accessed October 12, 2006.
  15. National Comprehensive Cancer Network. Clinical practice guidelines in oncology–v.2.2006: colon cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf. Accessed October 12, 2006.
  16. National Comprehensive Cancer Network. Clinical practice guidelines in oncology–v.2.2006: rectal cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf. Accessed October 12, 2006.
  17. Diemunsch P, Grélot L. Potential of substance P antagonists as antiemetics. Drugs. 2000;60:533–546.
  18. Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs. 1996;52:639–648.
  19. Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003;39:1074–1080.
  20. Gralla RJ, Roila F, Tonato M, for the Multinational Association for Supportive Care in Cancer. Perugia 2004 antiemetic guidelines. Slides presented at: Perugia International Cancer Conference VII: Consensus Conference on Antiemetic Therapy; March 29–31, 2004; Perugia, Italy. Last updated September 1, 2005.
  21. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–The Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112–4119.
  22. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al, on behalf of the Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–3098.
  23. Herrstedt J, Muss HB, Warr DG, et al, on behalf of the Aprepitant Moderately Emetogenic Chemotherapy Study Group. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005;104:1548–1555.
  24. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–2830.
  25. IMS HEALTH, Formulary Focus™. June 2006.
  26. Centers for Medicare & Medicaid Services. Decision memo for aprepitant for chemotherapy-induced emesis (CAG-00248N). Available at: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=133. Accessed October 12, 2006.
  27. Wilder-Smith OHG, Borgeat A, Chappuis P, Fathi M, Forni M. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer. 1993;72:2239–2241.
 
20850663(2)-07/08-EME